Welcome to our dedicated page for Eloxx Pharmaceut SEC filings (Ticker: ELOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eloxx Pharmaceut's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eloxx Pharmaceut's regulatory disclosures and financial reporting.
Eloxx Pharmaceuticals director Steven D. Rubin reported routine equity compensation activity. On January 24, 2026, he exercised 1,875 restricted stock units (RSUs), receiving an equal number of common shares at $0.00 per share, lifting his direct common stock holdings to 14,625 shares.
Following this RSU conversion, Rubin still held 1,875 RSUs. Earlier, on September 19, 2025, he received a grant of 179,854 stock options for common stock at a $0.15 exercise price, vesting 1/36 on October 31, 2025, then in equal monthly installments over 35 months until September 2035.
Eloxx Pharmaceuticals’ President and CEO Sumit Aggarwal reported a series of compensation-related equity moves. On February 28, 2026, he exercised options to acquire 260,946 shares of common stock at $0.15 per share, bringing his directly held common stock to 1,672,756 shares.
Earlier, on January 24, 2026, 15,000 restricted stock units converted into an equal number of common shares. On September 19, 2025, he received an award of 1,000,000 common shares and 3,597,090 stock options with a $0.15 exercise price expiring in 2035. On August 14, 2025, he exercised options to acquire 196,880 shares at an exercise price of $0.0001 per share.
Footnotes state that several older options granted in 2021–2023 were cancelled and replaced with new options at lower exercise prices, and that the board accelerated vesting or waived performance conditions in connection with certain exercises and grants.
Eloxx Pharmaceuticals director Alan Edmund Walts reported equity compensation activity, not open‑market trading. On January 24, 2026, he exercised 1,875 restricted stock units, receiving an equal number of common shares at a stated price of $0.00 per share, bringing his directly held common stock to 15,567 shares.
A prior grant on September 19, 2025 awarded him a stock option for 395,680 shares of common stock at an exercise price of $0.15 per share, expiring on September 19, 2035. The option vests over 36 months, and the RSUs vested 50% after one year with the balance in two annual installments.
Eloxx Pharmaceuticals, Inc. informs stockholders that holders of a majority of its common stock approved corporate actions by written consent on April 28, 2026. The Board and Majority Stockholders approved (1) a First Amendment increasing the 2018 Equity Incentive Plan share reserve to 20,000,000 shares, (2) an amended and restated 2018 Equity Incentive Plan with an ISO limit of 80,000,000 shares and an evergreen extension to January 1, 2036, and (3) a reverse stock split to be effected at a Board-determined ratio between 1-for-2 and 1-for-20 to be implemented, if any, on or prior to the one-year anniversary of the record date. The Information Statement states there were 7,573,935 shares of Common Stock outstanding as of the record date and notes the Company intends to file a registration statement covering shares under the Restated 2018 Plan.
Eloxx Pharmaceuticals, Inc. is seeking to raise capital through a public offering of common stock and pre-funded warrants, with the closing contingent on securing a listing of its common stock on the Nasdaq Capital Market under the symbol “ELOX”. The company is currently quoted on the OTC Expert Market and was previously delisted from Nasdaq after failing to meet market value requirements and becoming delinquent in SEC filings.
Eloxx is a clinical-stage biopharmaceutical company focused on exaluren, a ribosome-modulating small molecule being developed for Alport syndrome with nonsense mutations and autosomal dominant polycystic kidney disease, and on ZKN-013, which is licensed to Almirall for rare skin diseases. The company reported a net loss of $6.0 million in 2025 and $3.8 million for the three months ended March 31, 2026, had $6.4 million in cash and cash equivalents and an accumulated deficit of $304.3 million, and its auditors expressed substantial doubt about its ability to continue as a going concern.
Eloxx Pharmaceuticals reported a larger net loss of $3.8M for the quarter ended March 31, 2026, compared with $1.7M a year earlier, as it increased spending on drug development and corporate overhead.
Research and development expenses rose to $1.7M and general and administrative costs climbed to $2.1M. Eloxx ended the quarter with $6.4M in cash, after raising about $7.0M through pre-funded warrant financings and eliminating its remaining debt. Management and the auditors state that recurring losses and limited cash create substantial doubt about the company’s ability to continue as a going concern, absent additional capital.
Domicilium Real Estate Fund III LP filed an initial ownership report for Eloxx Pharmaceuticals, Inc., disclosing indirect holdings in the company. The filing shows indirect ownership of 157,138 shares of common stock and a separate indirect position of 1,250,000 common shares.
The report also lists indirect holdings of Pre-Funded Warrants exercisable for 20,841,782 and 1,372,652 shares of common stock at an exercise price of $0.0100 per share. According to the disclosure, these Pre-Funded Warrants have no expiration date and are exercisable at any time, subject to a 4.99% beneficial ownership cap that limits exercises if they would push the holder above 4.99% of outstanding common stock.
Eloxx Pharmaceuticals disclosed a Schedule 13G showing Domicilium-related entities and Daniel Simon together report beneficial ownership of up to 1,407,138 shares, representing 18.6% of the common stock. The filing lists shared voting and dispositive power for those shares and states they are held for advisory clients.
The filing is signed by Daniel Simon as managing member and includes a joint filing agreement among the Domicilium entities.
Eloxx Pharmaceuticals disclosed that Coastlands-related reporting persons collectively hold 1,250,000 shares of Common Stock, representing 16.51% of the class. The filing states the ownership calculation uses 5,071,935 shares outstanding as of March 12, 2026 and reflects 2,500,000 shares issued on April 27, 2026 upon exercise of pre-funded warrants. The reporting persons state shared voting and dispositive power over 1,250,000 shares and disclaim control-group status and beneficial ownership beyond their pecuniary interest; a 4.99% beneficial ownership limitation for certain pre-funded warrants is noted.
Coastlands Capital LP filed an initial ownership report for Eloxx Pharmaceuticals, Inc., showing indirect holdings in the company. The filing reports 1,250,000 shares of common stock held indirectly through Coastlands Capital LP. It also reports Pre-Funded Warrants that are exercisable into 29,362,243 shares of common stock at an exercise price of $0.01 per share.
The Pre-Funded Warrants have no expiration date and are exercisable at any time after issuance, subject to a 4.99% beneficial ownership limit, which restricts exercise if it would push the holder above that ownership threshold. The reporting persons jointly file and each disclaims beneficial ownership beyond their pecuniary interest.